NASDAQ:SRDX - Nasdaq - US8688731004 - Common Stock - Currency: USD
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: BSX
Investors need to pay close attention to SRDX stock based on the movements in the options market lately.
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Surmodics (NASDAQ:SRDX) just reported results for the third quarter of 2024.Sur...
SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.